Traveling Exhibit of Cancer Educational Resources

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE) has joined with its first partner, the American Association for Cancer Education (AACE), to put together an international traveling exhibit of educational materials and resources for cancer education, to be shown at many of the smaller cancer congresses around the world, Charles D. Sherman, Jr., MD, told Oncology News International.

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE)has joined with its first partner, the American Association for CancerEducation (AACE), to put together an international traveling exhibit ofeducational materials and resources for cancer education, to be shown atmany of the smaller cancer congresses around the world, Charles D. Sherman,Jr., MD, told Oncology News International.

Dr. Sherman is director of the Highland Hospital Cancer Treatment Center,Rochester, NY, and co-director of INCE, along with Richard R. Love, MD,of the University of Wisconsin, Madison.

The INCE expects the initial collection to be exhibited at the AACEmeeting in Atlanta next October; it then will be reviewed and refined fordisplay elsewhere. An offshoot of this project is the production of anInternational Directory of materials and resources for cancer education,as well as individuals and organizations involved in cancer education.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content